Endoluminal Gastric Surgery: the Modern Era of Minimally Invasive Surgery

Rosen, Michael J.; Heniford, B. Todd

doi:10.1016/j.suc.2005.05.010

Cited by 37 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lymph node metastases are very rare and routine lymphadenectomy is not required [6,21]. Wedge resection of gastric GISTs has been widely reported to be successful [3,7,9,10,22,23]. There is also evidence that laparoscopic resection of GISTs is effective [24][25][26][27] with minimal morbidity and no reported mortality [15].…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal stromal tumors (GIST) and laparoscopic resection

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Gastrointestinal stromal tumors (GIST) and laparoscopic resection

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The reference documents retrieved by the key words ‘gastric, cancer, laparoscopic, surgery’ were 22 in PubMed with the following limits activated: Humans, Clinical Trial, Meta-Analysis, Randomized Controlled Trial, Review, English, Core clinical journals, published between January 2000 and December 2009 [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23]. Data regarding the following factors were considered about the clinical benefit and quality of life: operation time, blood loss, hospitalization days, duration of fasting after operaton, number of excised lymph nodes, incidence of postoperative complication.…”

Section: Methodsmentioning

confidence: 99%

Disadvantage of Operation Cost in Laparoscopy-Assisted Distal Gastrectomy under the National Health Insurance System in Japan

Hoya

Taki²,

Tanaka³

et al. 2010

Dig Surg

View full text Add to dashboard Cite

Background: The utility and problems including the socioeconomic aspect of laparoscopy-assisted distal gastrectomy for gastric cancer have not been fully evaluated. Subjects and Methods: We compared open distal gastrectomy and laparoscopy-assisted distal gastrectomy for the clinical benefit, quality of life, and problems of operation cost by the reference documents in which the difference between open distal gastrectomy and laparoscopy-assisted distal gastrectomy was examined in detail. The reference documents retrieved by the key words ‘gastric, cancer, laparoscopic, surgery’ were 22 in PubMed with the following limits activated: Humans, Clinical Trial, Meta-Analysis, Randomized Controlled Trial, Review, English, Core clinical journals, published in the last 10 years. Results: The operation time of laparoscopy-assisted distal gastrectomy is longer than that of open distal gastrectomy. However, if skilled, the blood loss of laparoscopy-assisted distal gastrectomy is less, the hospitalization days and the duration of fasting after laparoscopy-assisted distal gastrectomy are shorter than those after open distal gastrectomy. The number of excised lymph nodes and the incidence of postoperative complications were similar between laparoscopy-assisted distal gastrectomy and open distal gastrectomy. On the other hand, in the national health insurance system, the operation fee of open distal gastrectomy was USD 6,637 as compared to USD 7,586 for laparoscopy-assisted distal gastrectomy. In spite of the USD 949 difference in the operation fee, the use of disposable instruments for laparoscopy-assisted distal gastrectomy results in a deficit of USD 1,500 over open distal gastrectomy. Conclusion: In spite of the medical superiority of laparoscopy-assisted distal gastrectomy over open distal gastrectomy (if a skilled surgeon operates) as less invasive surgery, laparoscopy-assisted distal gastrectomy is associated with less financial benefit to the hospital as compared to open distal gastrectomy in the current Japanese health insurance system.

show abstract

“…This approximation is enabled by two additional assumptions, namely that the contribution from the plasma is negligible (which is generally the case several minutes after injection given the low volume of plasma in the tissue) and that the two tracers behave identically in the tissue, with the exception of binding. Provided that these assumptions apply, it can be shown that the dual-tracer model reduces to BP = F T =F UT − 1; [2] enabling BP to be estimated with a simple ratio of the targeted and untargeted tracers from a single dual-channel image. Relaxing the requirement to acquire dynamic measurements of tracer kinetics in the tumor allows the analysis to be completed with ex vivo specimens, and thus, it provides an independent method to validate BP values in tumors inaccessible to in vivo planar imaging.…”

Section: Ex Vivo Quantification Of Available Receptor Density In Orthmentioning

confidence: 99%

“…Additionally, because many of these receptors are involved in cell signaling pathways that lead to enhanced cell proliferation, reduced apoptosis, and drug resistance, they are increasingly being targeted with receptor-specific therapies that interfere with these pathways to block signaling and inhibit tumor growth. As efforts to personalize cancer treatment by targeting patients' specific receptor expression profiles expand (1)(2)(3)(4), the ability to noninvasively quantify the availability of those receptors in living tissue would be an important development with broad implications for drug development programs and for monitoring a patient's response to therapies.…”

mentioning

confidence: 99%

Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo

Davis

Samkoe²,

Tichauer

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The up-regulation of cell surface receptors has become a central focus in personalized cancer treatment; however, because of the complex nature of contrast agent pharmacokinetics in tumor tissue, methods to quantify receptor binding in vivo remain elusive. Here, we present a dual-tracer optical technique for noninvasive estimation of specific receptor binding in cancer. A multispectral MRI-coupled fluorescence molecular tomography system was used to image the uptake kinetics of two fluorescent tracers injected simultaneously, one tracer targeted to the receptor of interest and the other tracer a nontargeted reference. These dynamic tracer data were then fit to a dual-tracer compartmental model to estimate the density of receptors available for binding in the tissue. Applying this approach to mice with deep-seated gliomas that overexpress the EGF receptor produced an estimate of available receptor density of 2.3 ± 0.5 nM (n = 5), consistent with values estimated in comparative invasive imaging and ex vivo studies.

show abstract

Endoluminal Gastric Surgery: the Modern Era of Minimally Invasive Surgery

Cited by 37 publications

References 47 publications

Gastrointestinal stromal tumors (GIST) and laparoscopic resection

Gastrointestinal stromal tumors (GIST) and laparoscopic resection

Disadvantage of Operation Cost in Laparoscopy-Assisted Distal Gastrectomy under the National Health Insurance System in Japan

Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo

Contact Info

Product

Resources

About